Greater Philadelphia. The one-year Inovio Pharmaceuticals Inc. stock forecast points to a potential upside of 43.88. Let’s start up with the current stock price of Inovio Pharmaceuticals Inc. (INO), which is $8.55 to be very precise. MANAGER, STRATEGIC SOURCING (Former Employee) - San Diego, CA - September 12, 2017. Phone Number 267-440-4200. A look at the daily price movement shows that the last close reads $6.61, with intraday deals fluctuated between $6.12 and $6.68. ET. The stock had previously closed at $6.17. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) hit a new 52-week low during trading on Monday . INOVIO Pharmaceuticals, Inc. is committed to a policy of equal employment opportunity. As of March 12, 2020, the novel coronavirus and the illness it causes, COVID-19, had infected more than 120,000 people and caused approximately 4,300 deaths worldwide. Its product pipeline include VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. Inovio Pharmaceuticals, Inc. NASDAQ Updated Dec 4, 2021 12:50 AM INO 6.17 0.44 (6.66%). Legal Name Inovio Pharmaceuticals, Inc. Stock Symbol NASDAQ:INO. The average equity rating for INO stock is currently 2.50, trading closer to a bullish pattern in the stock market. About Inovio Pharmaceuticals. Data is currently not available. $6.885. Inovio Pharmaceuticals Inc also received an overall rating of 56, putting it above 56% of all stocks. Contact Email ino@inovio.com. Raw Stochastic average of Inovio Pharmaceuticals Inc. in the period of last 50 days is set at 16.47%. Inovio Pharmaceuticals Continues to Point One Way. Find the latest Inovio Pharmaceuticals, Inc. (INO) stock discussion in Yahoo Finance's forum. Nasdaq 100. INOVIO’s first-of-their-kind DNA medicines are precisely designed DNA plasmids delivered through INOVIO’s proprietary smart device — CELLECTRA ® — directly into the body’s cells to produce an immune response robust enough to potentially treat or prevent disease.. How INOVIO’s DNA Medicines Work: MOA No news for in the past two years. The photo-film mission will see Wagner flying … The latest Tweets from INOVIO Pharmaceuticals (@InovioPharma). The share float percentage for the stock currently stands at 38.29%. Inovio Pharmaceuti In addition, the company is partnering with Sinovac Biotechnology and Advaccine to investigate the potential of INO-4800 as a booster shot. Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. Powering DNA Medicines. Gabe Kolesari Associate Director of Infrastructure at School Specialty, Inc. Sussex, WI. This compares to loss of $0.22 per share a year ago. Their forecasts range from $6.00 to $35.00. While I only worked for Innovio for a short period of time I truly enjoyed the team of people that I worked with. In that particular session, Stock kicked-off at the price of $6.66 while reaching the peak value of $6.78 and lowest value recorded on the day was $6.57. The company is headquartered in Plymouth Meeting, Pennsylvania and was founded by Joseph Kim in 1983. Add to Watchlist. Due to its regulatory troubles in the U.S., Inovio and its partner, Wall Street Stock Market & Finance report, prediction for the future: You'll find the Inovio Pharmaceuticals share forecasts, stock quote and buy / sell signals below.According to present data Inovio Pharmaceuticals's INO shares and potentially its … Inovio Pharmaceuticals Inc currently has the 141th highest Short-Term Technical score in the Biotechnology industry. Shares of coronavirus vaccine developer Inovio Pharmaceuticals(NASDAQ:INO)are down 11% to $8.50 apiece as of 10:30 a.m. EDT. INO stock dropped 6% after second-quarter earnings and it's high-flying days may be over. Inovio Job Experience. Phone 1 267 440-4200. View Inovio Pharmaceuticals, Inc. INO investment & stock information. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 17.53%. INO stock is now a blood-in-the-street opportunity as Inovio is currently facing a temporary hurdle from the FDA. Inovio Pharmaceuticals, Inc engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Biotechnology is ranked 89 out of … by Zacks Equity Research Published on November 09,2021. Do the numbers hold clues to what lies ahead for the stock? The stock had previously closed at $6.17. The stock traded as low as $5.75 and last traded at $5.89, with a volume of 40745 shares. Inovio Pharmaceuticals Shares Drop, Get a Downgrade. The company reported second-quarter earnings after markets closed on Monday. Inovio Pharmaceuticals (INO) Reports Q3 Loss, Tops Revenue Estimates. INOVIO’s first-of-their-kind DNA medicines are precisely designed DNA plasmids delivered through INOVIO’s proprietary smart device — CELLECTRA ® — directly into the body’s cells to produce an immune response robust enough to potentially treat or prevent disease. 7 Wall Street analysts have issued 12 month price targets for Inovio Pharmaceuticals' shares. If we look at who the major shareholders are, we find that insiders hold 1.65% of Inovio Pharmaceuticals Inc. shares while 37.66% of the shares are in the hands of institutional holders. On average, they anticipate Inovio Pharmaceuticals' stock price to reach $13.17 in the next twelve months. Clinical Supplies Manager at Inovio Pharmaceuticals Inc. The Stock rose vividly during the last session to $8.39 after opening rate of $8.23 while the lowest price it went was recorded $8.03 before closing at $8.26.Recently in News on July 26, 2021, INOVIO to Report Second Quarter 2021 Financial … Inovio Pharmaceuticals Inc's score of 87 means it scores higher than 87% of stocks in the industry. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Plymouth Meeting, PA The market cap for the stock reached $1.81 billion, with 207.63 million shares outstanding and 204.08 million shares in the current float. Inovio Pharmaceuticals Inc. Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, … Inovio Pharmaceuticals EPS beats by $0.04, misses on revenue Seeking Alpha - 11/9/2021 4:11:04 PM: INOVIO Reports Third Quarter 2021 Financial Results PR Newswire (US) - 11/9/2021 4:05:00 PM: INOVIO wins FDA clearance to proceed with late-stage study for COVID-19 shot Seeking Alpha - 11/9/2021 8:35:04 AM Looking at the stock we see that its previous close was $7.08 and the beta (5Y monthly) reads 0.65 with the day’s price range News Inovio Pharmaceuticals Inc.INO. Inovio Pharmaceuticals (INO) Reports Q3 Loss, Tops Revenue Estimates Inovio (INO) delivered earnings and revenue surprises of 12.12% and 53.68%, respectively, for the quarter ended September 2021. INO: Get the latest Inovio Pharmaceuticals stock price and detailed information including INO news, historical charts and realtime prices. INOVIO Pharmaceuticals, Inc. is committed to a policy of equal employment opportunity. Company Type For Profit. INOVIO Pharmaceuticals, Inc. (INOVIO) is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, … Industry Biotechnology. A look at the daily price movement shows that the last close reads $6.61, with intraday deals fluctuated between $6.12 and $6.68. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 17.53%. Among other things, Inovio plans to launch phase 3 clinical trials for its DNA coronavirus vaccine candidate INO-4800. +0.145 (+2.15%) DATA AS OF Oct 25, 2021 10:57 AM ET. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies. Inovio Pharmaceuticals Inc. closed $12.06 short of its 52-week high ($19.00), which the company achieved on February 2nd. INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that Dr. J. Joseph Kim, President and CEO, will present at the following investor conferences in September: Post-Market 0.04 (0.65%) Steve McNett Crane operator at Sugarland Crane NCCCO# 1709145608 TSS, BTF, STC Exports 9/30/22 Let's kick the tires again on this speculative stock. Raw Stochastic average of Inovio Pharmaceuticals Inc. in the period of last 50 days is set at 16.47%. INOVIO Pharmaceuticals, Inc. is committed to a policy of equal employment opportunity. Company Type For Profit. Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Inovio Pharmaceuticals is a biotechnology company focused on rapidly bringing to market DNA medicines to treat, cure and/or protect people from infectious diseases. Inovio Pharmaceuticals Inc. closed $11.78 below its 52-week high ($19.00), which the company reached on February 2nd. The share float percentage for the stock currently stands at 38.29%. The consensus among Wall Street analysts is that investors should "hold" Inovio Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INO, but not buy additional shares or sell existing shares. Inovio Pharmaceuticals Inc. (INO): Stocks Technical analysis and Trends. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 1… Get the latest Inovio Pharmaceuticals, Inc. INO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Several research analysts have recently commented on the company. The company was founded by David B. Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The Bottom Line on Inovio Pharmaceuticals’ Stock The first time I highlighted opportunity in Inovio Pharmaceuticals (NASDAQ:INO), it traded at just $4.86 a … #biotech #DNAMedicines #DNA #HPV #cancer #infectiousdisease #immunotherapy #dnavaccine. Inovio Pharmaceuticals ( INO-6.66%) Q3 2021 Earnings Call Nov 09, 2021, 4:30 p.m. Suite 110. Phone Number 267-440-4200. Inovio Pharmaceuticals Inc. (NASDAQ:INO)’s Major holders. Inovio Pharmaceuticals (NASDAQ: INO) stock is pushing higher on Tuesday after providing investors with an update on its Covid-19 vaccine. FDA Lifts Partial Clinical Hold on INNOVATE Phase 3 Segment INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced that the U.S. Food and Drug Administration (FDA) provided … Inovio Pharmaceuticals Inc. (INO): Stocks Technical analysis and Trends. Find the latest Inovio Pharmaceuticals, Inc. (INO) stock quote, history, news and other vital information to help you with your stock trading and investing. Photographer Florian Wagner will cross the continent documenting critical water systems. Royal Bank of Canada reduced their target […] Inovio Pharmaceuticals Inc. (NASDAQ:INO) price closed lower on Friday, December 03, dropping -6.66% below its previous close. Inovio Pharmaceuticals. This suggests a possible upside of 81.6% from the stock's current price. In comparing Inovio Pharmaceuticals Inc. (INO)’s stock with other industry players reveals that stock’s latest price change of 0.14% and that of -38.14% over the past 12 months is in competing position with that of Johnson & Johnson (JNJ) which saw its stock price fall by -0.71% in the recent trading and went through an increase of 10.78% in past 12-month … Inovio Pharmaceuticals, Inc. Common Stock (INO) Nasdaq Listed. Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and … The stock traded as low as $5.75 and last traded at $5.89, with a volume of 40745 shares. Share your opinion and gain insight from other stock traders and investors. This means that the stock's trading pattern over the last month have been neutral. Plymouth Meeting, Pennsylvania 19462-1111. If we look at who the major shareholders are, we find that insiders hold 1.65% of Inovio Pharmaceuticals Inc. shares while 37.66% of the shares are in the hands of institutional holders. Inovio Pharmaceuticals is a biotechnology company developing and commercializing DNA immunotherapies for the treatment of cancer and infectious diseases. WOODSTOCK, Illinois, May 15, 2018 /PRNewswire/ — OWC®, a leading zero emissions Mac and PC technology company, has announced their support for photojournalist Florian Wagner’s African Waters 360° project.
Clear Blue Wake-up Stick, Average Monthly Salary In Seychelles, Cambridge, Massachusetts, United States Time, Mayari Birkenstock Oiled Leather, Soft Skills Development Goals Examples, Psychological Benefits Of Exercise, Aruba Weather In February, Fda-approved Nitric Oxide Supplements, Cs Constantine Flashscore, Example Of Chain Isomerism, Do Plants Do Cellular Respiration, Physical Signs Of Not Eating Enough,
Clear Blue Wake-up Stick, Average Monthly Salary In Seychelles, Cambridge, Massachusetts, United States Time, Mayari Birkenstock Oiled Leather, Soft Skills Development Goals Examples, Psychological Benefits Of Exercise, Aruba Weather In February, Fda-approved Nitric Oxide Supplements, Cs Constantine Flashscore, Example Of Chain Isomerism, Do Plants Do Cellular Respiration, Physical Signs Of Not Eating Enough,